TN-LUBRIZOL
Eastman and Lubrizol have successfully partnered on improving adhesion strength of thermoplastic elastomers (TPEs) overmolded onto Eastman Tritan™ copolyester TX1501HF. The collaboration stemmed from a mutual recognition of overmolding's importance in manufacturing while delivering improved product performance and aesthetics in consumer goods when using Eastman’s sustainable material, Tritan™ Renew, and Lubrizol’s ESTANE® ECO, renewably sourced TPU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430342572/en/
Eastman and Lubrizol collaborate to enhance TPE overmolding adhesion with sustainable materials. (Photo: Business Wire)
The companies researched how specific processing variables impact the adhesion strength of overmolded samples produced through 2K injection molding. The study’s findings are believed to be applicable across various TPE and substrate combinations. This is of particular interest when mechanical interlocks cannot be used, and material changes are not feasible but improvements in adhesion strengths are desired.
By optimizing key TPE processing variables like mold temperature, pack and hold time, and TPE barrel temperature, the research team achieved a notable 124% improvement in adhesion strength compared to values obtained using non-ideal processing conditions. An additional improvement in adhesion strength was observed when Lubrizol’s ESTANE® ECO 12T80E and 16T85 TPU grades were used. These grades displayed the highest peel strength values (> 310 N) of all TPEs evaluated in this preliminary study.
“This was a unique opportunity for two leading material companies to leverage sustainable multi-material solutions that enable customer innovations and expand the limits of consumer product experiences,” said Vince Haas, Lubrizol’s engineered polymers senior business director.
“This effort has advanced our understanding of overmolding and TPEs, providing valuable guidance for engineers and manufacturers looking to improve overmolded product strength,” said Courtland Jenkins, Eastman’s commercial director for engineered solutions. “These findings open doors for new and innovative product designs, particularly when using recycled content.”
For a detailed view of the study, access the white paper [link].
NPE2024 attendees are invited to visit Lubrizol’s booth #S35017, May 6-10 in Orlando, Fla., to see Tritan™ Renew materials overmolded with ESTANE® ECO technology and can also gain deeper insights through a joint webinar hosted by UL Prospector at 9 a.m. on Wednesday, June 12. Webinar registration link here [link].
About Eastman
Eastman is a global specialty materials company that produces a broad range of products found in items people use every day. With the purpose of enhancing the quality of life in a material way, Eastman is committed to safety, innovation and sustainability. Headquartered in Kingsport, Tennessee, USA, it had 2023 revenues of approximately $9.2 billion. For more information, visit www.eastman.com.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a specialty chemical company whose science delivers sustainable solutions to advance mobility, improve wellbeing and enhance modern life. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has more than 8,000 employees. For more information, visit www.Lubrizol.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430342572/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eurobank Collaborates with LTIMindtree for a Multi-Year Banking Technology Program17.2.2025 09:30:00 CET | Press release
Cements relationship with the opening of Global Delivery Center in Pune, India Eurobank S.A. (“Eurobank”), a subsidiary of “Eurobank Ergasias Services and Holdings S.A.” (“Eurobank Holdings”) a leading banking group in Athens, Greece and LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, have joined forces to initiate a multi-year mutually beneficial cooperation focused on enhancing customer experience by improving banking operations and building innovative IT services for Eurobank and its subsidiaries. The collaboration has been enabled by Fairfax Digital Services (A Fairfax Company) andwill include the establishment of a Global Delivery Center in India. Global Delivery Center, Pune – Executing a shared vision Strengthening the commitment to innovation, customer experience, and excellence in banking technology, Eurobank & LTIMindtree, powered by Fairfax Digital Services, officially inaugurated their new Global Delivery Center at the LTI
ATP Media Selects SES for Tennis Content Delivery Worldwide17.2.2025 08:50:00 CET | Press release
SES SCORE platform and hybrid distribution to power broadcasts of 58 ATP tournaments that reach a billion global fans through 70+ broadcast partners SES announced today a new agreement to deliver and manage video content for ATP Tour events around the world using Secure Reliable Transport (SRT) and its unique Sports Content Orchestration Enabler (SES SCORE) platform enabled by SES’s hybrid IP, fibre and satellite distribution network. With more than 200,000 hours of live content per year from 3,200 tennis matches across various ATP Masters 1000, ATP 500 and ATP 250 tournaments, SES SCORE gives ATP Media an easy-to-use, centralized platform to manage and deliver its content. ATP Media’s 70+ broadcast partners can select from a variety of video feeds, audio, metadata and other content when creating their broadcasts with a simplified booking process. “We wanted to give our broadcast partners unrestricted access to up to 10 Court Feeds we produce at our ATP Masters 1000 tournaments, as wel
Textron Aviation to Open New Service Facility at Essendon Fields Airport, Expanding Capabilities in Australia17.2.2025 06:00:00 CET | Press release
Textron Aviation announced today an expansion of its footprint in Australia with the construction of a larger and modernized service facility at Essendon Fields Airport in Melbourne to maximize support for Cessna, Beechcraft and Hawker customers in the region. The new facility will add more space for servicing aircraft, aiding in faster scheduling with minimal down time to keep customers flying. Construction is set to begin March 2025 and Textron Aviation expects to be fully functional in the new facility by early 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213028444/en/ L-R: Stefan Wenger, vice president, International Customer Service Centers, Textron Aviation, Brian Rohloff, senior vice president, Global Customer Support, Textron Aviation, Brendan Pihan, CEO, Essendon Fields Airport, Peter Funder, general manager development, Essendon Fields Airport at the new facility site in Melbourne. (Photo: Craig Moodie)
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)16.2.2025 00:00:00 CET | Press release
OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications referencing Prolia and Xgeva, respectivelyMarks Samsung Bioepis’ 10th and 11th product and first endocrinology treatment approved by the EC – adding to its growing portfolio of biosimilars Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars referencing Prolia and Xgeva – formerly referred to as SB16. OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. XBRYK, referencing Xgeva, has been approved for the prevention of skel
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)15.2.2025 00:50:00 CET | Press release
In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically meaningful improvements in quality-of-life measures, and demonstrated well-tolerated safety profile Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214768549/en/ “
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom